A firmness brief that only says “add the tripeptide” still cannot open a sample request. Tripeptide-2 is a synthetic three-amino-acid INCI. The grade on this page is a white to off-white powder, HPLC purity 99% or higher, soluble in water and only slightly soluble in ethanol. Public inventories describe the name as a peptide that contains tyrosine and valine residues, with a skin-conditioning function.
When the same brief also prints Progeline, the drum may be a different INCI. Clear that gate before you ask for a price: Progeline Usually Means Trifluoroacetyl Tripeptide-2.
Read the specification block, not the hero line
On the product page the H1 and the specification table say INCI Tripeptide-2. The short buy line above that table has, at times, named Trifluoroacetyl Tripeptide-2 instead. Those are two inventory names. Purchasing follows the specification block and the COA, not a marketing sentence that borrowed the neighboring peptide.
Write Tripeptide-2 when the label and the assay must show the underivatized peptide. Ask the supplier to print that INCI on the COA before the sample ships. If the COA comes back as Trifluoroacetyl Tripeptide-2, you received the other grade—even if the email subject still says Tripeptide-2.
The description text on the same page also uses progerin language. Published progerin work buyers usually quote was run on trifluoroacetyl-tripeptide-2, including commercial Progeline files. Keep those percentages and mechanism claims with the named active that published them. Do not treat a hero sentence as proof that this bare powder lot carries the same study.
What the INCI is locking
Secondary CosIng mirrors describe Tripeptide-2 as a synthetic peptide containing tyrosine and valine, inventory function skin conditioning, and often list reference 59875. Many of those mirrors show no CAS for the bare name. Do not paste CAS 64577-63-5 under a Tripeptide-2 header. That number belongs with Trifluoroacetyl Tripeptide-2, whose page prints sequence TFA-Val-Tyr-Val-OH, formula C21H28F3N3O6, and the same CAS.
This bare-powder page does not print an amino-acid sequence in the specification block. Do not assume the COA will read TFA-Val-Tyr-Val unless you ordered the trifluoroacetyl INCI. If your regulatory pack requires a sequence line, ask for it in the sample email and match it to the INCI you locked.
What “for skin” is deciding
Searches for tripeptide-2 for skin and for skin benefits sound like benefit copy. For a formulator they are a placement question: which chassis, which phase, and which claim language is still honest for the lot you will weigh.
Inventory wording for the bare name stops at skin conditioning. The product specification places the powder in anti-aging serums, creams, and masks aimed at firmness and elasticity, including eye and neck formats, plus daily moisturizers and body lotions in the use notes. That is enough to start a water-phase or emulsion trial at the suggested band. It is not enough to paste a finished-product wrinkle or “lifted jawline” claim onto the raw material. Those sentences, when they exist, stay with the commercial file that measured them.
Dose this powder from its own TDS. A firmness story does not change the INCI.
How this powder enters the water phase
Suggested use on the product page is 0.01–0.05%. Dissolve it in the water phase below 40°C. Keep the system near pH 4.0–7.0. The solubility line is water-soluble, only slightly soluble in ethanol—so an oil phase or a high-ethanol base is the wrong default. If a bench sample will not clear in water, check temperature and whether a glycerin–water trade solution was expected instead of this neat powder.
Store the powder cool, dry, and protected from light. The specification block says 2–8°C. Avoid strong oxidizing agents in the same phase. The use notes also say to keep finished goods in airtight packs away from light; that is a finished-product handling hint, not a substitute for the peptide TDS.
A glycerin–water–dextran Progeline-type blend and this ≥99% powder do not share one use percent. Trade files for that blend often quote about 0.5–2% of the whole solution. Copying 2% onto this powder overdoses the pilot. Copying 0.01–0.05% onto the dilute blend underdoses it. Read the TDS for the physical form you will receive, then set the pilot from that document.
Pairing still means separate purchase lines
The page lists companions that can share a chassis:
- Hyaluronic Acid for the water-phase humectant line
- Niacinamide for a separate vitamin line
- Palmitoyl Tripeptide-1 for a palmitoylated signal peptide, not this bare tripeptide
Each remains its own INCI, assay, and COA. One “firming peptide” line on the PO does not authorize the warehouse to swap in palmitoyl tripeptide-1, a copper peptide, or the trifluoroacetyl grade. Write every INCI you need. Quote them as separate SKUs.
Autocomplete that sends the wrong RFQ
Suggestions under “tripeptide-2” often jump to Tripeptide-29, injection, and dosage. Tripeptide-29 is another peptide. An injectable dose is not a cosmetic use level for this powder. If the project is topical, say so in the inquiry and attach the cosmetic INCI. Do not paste a clinic protocol into a sample request.
Progeline and trifluoroacetyl mix-ups are the other common fork. They are handled in the companion note linked above. Send the sample request only after you know which of the two INCIs the label will carry.
What to send before the first sample ships
Put these lines in the message to the supplier:
- INCI Tripeptide-2, and an explicit note that the brief is not Trifluoroacetyl Tripeptide-2
- Appearance: white to off-white powder; HPLC assay target (≥99% if that is your brief)
- Confirmation that CAS 64577-63-5 will not be printed on this COA unless you changed the INCI
- Solubility expectation: water; cool-down below 40°C; pH window 4.0–7.0
- Storage expectation if your QC requires the 2–8°C line
- Bench-sample pack size, plus COA, SDS, and TDS with the shipment
Batch documents and a sample are available from the product page. Match the sample COA to the specification block you wrote, then scale. A clear bare-INCI line usually returns documents and a quote. A vague “firming peptide,” a hero-line mix-up, or an unmarked “Progeline” subject usually returns clarifying questions first.
